Tag: Zepbound
Feb 25, 2026 | 5 minutes read | Insight Flash
Novo Nordisk (NVO) shares declined following results from the REDEFINE-4 trial, where CagriSema achieved 23.0% weight loss at 84 weeks versus 25.5% f...
Learn More
Jan 15, 2025 | 5 minutes read | All Posts
Eli Lilly (LLY) facilitated the rollout of both its blockbuster GLP-1 drugs Mounjaro and Zepbound with bridge programs to drive early sales. But the ...
Learn More
Jul 16, 2024 | 5 minutes read | All Posts
Contact Sales for more....
Learn MoreStay Ahead of the Curve: Join Our Global Community and Get Access to Exclusive Consumer Market Insights, Industry Ranking Reports, Product News, and Market Updates from the Consumer Edge Insight Center